Keith Tapper
Stock Analyst at BMO Capital
(0.08)
# 4,128
Out of 4,786 analysts
5
Total ratings
20%
Success rate
-27.87%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Keith Tapper
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NGNE Neurogene | Maintains: Outperform | $60 → $45 | $14.52 | +209.92% | 3 | Nov 20, 2024 | |
| TSHA Taysha Gene Therapies | Initiates: Outperform | $5 | $1.93 | +159.07% | 1 | Jun 27, 2024 | |
| ACAD ACADIA Pharmaceuticals | Initiates: Outperform | $31 | $17.07 | +81.61% | 1 | Jun 27, 2024 |
Neurogene
Nov 20, 2024
Maintains: Outperform
Price Target: $60 → $45
Current: $14.52
Upside: +209.92%
Taysha Gene Therapies
Jun 27, 2024
Initiates: Outperform
Price Target: $5
Current: $1.93
Upside: +159.07%
ACADIA Pharmaceuticals
Jun 27, 2024
Initiates: Outperform
Price Target: $31
Current: $17.07
Upside: +81.61%